What is it about?
This article describes the development and validation of a novel multiparameter single-platform flow cytometry assay for the enumeration of circulating fibrocytes in the whole blood in the clinical setting and in multicenter clinical trials. The assay can be used to evaluate the utility and validity of blood fibrocyte count as an outcome measure in asthma.
Featured Image
Why is it important?
The assay is clinically valid because it is able to distinguish subjects with symptomatic asthma from healthy individuals and to detect significant differences among asthmatic patients on the basis of the level of asthma control and response to treatment. It gives highly reproducible results over time in healthy individuals and in asthmatic patients with stable conditions. It can be applied in multicenter clinical trials.
Perspectives
The description of a reliable and clinically applicable assay for the enumeration of fibrocytes in the whole blood is of paramount importance for the conduction of translational research and clinical studies in asthma and in other inflammatory and immunological disorders associated with tissue fibrosis, where fibrocytes may play a significant pathogenetic role.
Dr. Sabrina Mattoli
Avail Biomedical Research Institute
Read the Original
This page is a summary of: Enumeration of circulating fibrocytes for clinical use in asthma by an optimized single-platform flow cytometry assay, BBA Clinical, June 2014, Elsevier,
DOI: 10.1016/j.bbacli.2014.06.002.
You can read the full text:
Contributors
The following have contributed to this page
